Public Consultation – Draft Cost Recovery Implementation Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP
Page last updated: 1 February 2019
The Pharmaceutical Benefits Scheme (PBS) provides timely, reliable and affordable access to necessary medicines for Australians. The National Immunisation Program aims to reduce the incidence of vaccine-preventable diseases and protect individuals and the Australian community.
Cost Recovery involves the Australian Government charging the non-government sector some or all of the efficient costs of a specific government activity. That activity may include the provision of goods, services or regulation, or a combination of them.
The Draft Cost Recovery Implementation Statement (CRIS) for Listing Medicines on the PBS and Designated Vaccines on the NIP provides information on how the Department of Health proposes to implement the revised cost recovery arrangements announced by the Australian Government in December 2018.
After consultations with industry representatives during 2018, the Department of Health is releasing the draft CRIS for public consultation from 1 February to 17 February 2019.
The purpose of this consultation process is to:
- Provide stakeholders with an opportunity to provide feedback on the proposed changes prior to final approval of the regulation amendments required to implement the revised cost recovery model
- Ensure transparency on the proposed cost recovery arrangements prior to the commencement of the revised arrangements from July 2019.
Department of Health welcomes your feedback
Please provide your feedback through the following channels:
- Email – PBSimprovements@health.gov.au
- Hard copy – you can print a hard copy of your written comments and post to:
HTA Improvement Section
Technology Assessment and Access Division
Department of Health
GPO Box 9848,
Canberra ACT 2601, Australia
